Among the ICIs, PD-1/PD-L1 and CTLA-4 inhibitors have exhibited encouraging therapeutic outcomes, and some have been indicated for various tumor treatments since 2011 (Table 1), whereas others are under clinical trials [26]. The gene discussed is PDCD1; the disease is neoplasm.